WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer Reports Second-Quarter 2010 Results 11 August 2010
Pfizer to Offer Free Public Access to Mental Health Assessment Tools 23 July 2010
Pfizer Strengthens Manufacturing Capabilities in Asia 13 July 2010
Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial Program 25 June 2010
Phase 3 Study Showed MACUGEN® Improved Vision Over Standard of Care 07 June 2010
Pfizer Global Manufacturing Announces Plans to Reconfigure its Global Plant Network 20 May 2010
World Bank and Pfizer Announce Initiative to Help Improve Healthcare Delivery 26 April 2010
Pfizer Discontinues Phase 3 Trial of Sutent® in Advanced Hepatocellular Carcinoma 23 April 2010
Stemgent and Pfizer Announce Collaboration 16 April 2010
Pfizer Posts Details About Interactions With U.S. Physicians 01 April 2010
Pfizer Signs Long-Term Agreement to Supply Prevenar 13 to The World's Poorest Countries 24 March 2010
Pfizer Discontinues A Phase 3 Study Of Figitumumab 12 March 2010
Pfizer and Medivation Announce Results From Two Phase 3 Studies in Dimebon 04 March 2010
Pfizer's Prevnar 13 Recommended by CDC's Advisory Committee On Immunization Practices 25 February 2010
Lilly, Merck, And Pfizer Announce the Formation of the Asian Cancer Research Group, Inc. 24 February 2010
Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness 09 February 2010
Pfizer Reports Fourth-Quarter and Full-Year 2009 Results 04 February 2010
New Pfizer Pipeline Shows Progress And Growth In Vaccines, Biologics And High-Priority Disease Areas 28 January 2010
Pfizer and Strides Arcolab to Collaborate on Generic Products 07 January 2010
Pfizer Provides U.S. Regulatory Update On Prevnar 13™ Vaccine 02 January 2010
  • Start
  • Prev
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • Next
  • End

Business & Industry

  • GSK completes acquisition of Sierra Oncology
  • Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

Research & Development

  • Inhalable COVID-19 vaccine shows promise in rodent model
  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.